In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
Mineralys Therapeutics Inc (NASDAQ: MLYS) closed the day trading at $43.35 up 1.29% from the previous closing price of $42.8. In other words, the price has increased by $1.29 from its previous closing price. On the day, 1.5 million shares were traded. MLYS stock price reached its highest trading level at $44.38 during the session, while it also had its lowest trading level at $42.64.
Ratios:
For a better understanding of MLYS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 13 ’25 when Levy Adam Scott sold 10,758 shares for $42.01 per share. The transaction valued at 451,984 led to the insider holds 116,865 shares of the business.
Congleton Jon sold 15,100 shares of MLYS for $644,327 on Oct 13 ’25. The Chief Executive Officer now owns 831,305 shares after completing the transaction at $42.67 per share. On Oct 15 ’25, another insider, Rodman David Malcom, who serves as the Chief Medical Officer of the company, sold 10,369 shares for $43.01 each. As a result, the insider received 445,982 and left with 71,155 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 3362646272 and an Enterprise Value of 2548980224.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.35, which has changed by 2.0835736 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $43.88, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is 46.91%, while the 200-Day Moving Average is calculated to be 151.10%.
Shares Statistics:
Over the past 3-months, MLYS traded about 1.59M shares per day on average, while over the past 10 days, MLYS traded about 1259890 shares per day. A total of 65.73M shares are outstanding, with a floating share count of 50.57M. Insiders hold about 34.81% of the company’s shares, while institutions hold 64.76% stake in the company. Shares short for MLYS as of 1759190400 were 6883171 with a Short Ratio of 4.33, compared to 1756425600 on 7617115. Therefore, it implies a Short% of Shares Outstanding of 6883171 and a Short% of Float of 11.1499995.
Earnings Estimates
The dynamic stock of Mineralys Therapeutics Inc (MLYS) is currently attracting attention from 7.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$0.62, with high estimates of -$0.48 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$2.35 and -$3.44 for the fiscal current year, implying an average EPS of -$2.72. EPS for the following year is -$2.65, with 7.0 analysts recommending between -$1.89 and -$3.43.
